Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
ABC., imagem cardiovasc ; 35(3): eabc279, 2022. ilus
Artículo en Portugués | LILACS | ID: biblio-1411874

RESUMEN

A endocardite de valva nativa é uma doença incomum, complexa, e de alta morbimortalidade. Requer tratamento clínico prolongado, com várias complicações possíveis, e o seu tratamento cirúrgico é complexo e tecnicamente difícil. O ecocardiograma transtorácico e transesofágico são fundamentais na avaliação da doença, inclusive seus achados são parte dos critérios diagnósticos de endocardite. Adicionalmente, o ecocardiograma tridimensional (3D) contribui com detalhamento anatômico na avaliação das estruturas cardíacas acometidas pela doença. Mostramos um caso em que é ilustrado o papel da ecocardiografia no diagnóstico e avaliação de complicações da endocardite, comparando as imagens do ecocardiograma 3D pré-operatórias, com os achados durante o ato cirúrgico. (AU)


Native valve bacterial endocarditis is an uncommon, complex, and highly morbid disease that requires prolonged clinical treatment and challenging surgical interventions. Transthoracic and transesophageal echocardiography are paramount assessment tools whose findings are included in the diagnostic criteria. Three-dimensional echocardiography shows further realistic imaging details. Here we present a case demonstrating the role of echocardiography in the diagnosis of endocarditis and the identification of its complications to show how advanced imaging techniques may have a remarkable resemblance with in vivo surgical findings. (AU)


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Endocarditis/complicaciones , Endocarditis/terapia , Endocarditis/diagnóstico por imagen , Válvula Mitral/patología , Insuficiencia de la Válvula Mitral/cirugía , Ecocardiografía/métodos , Gentamicinas/uso terapéutico , Vancomicina/uso terapéutico , Ecocardiografía Transesofágica/métodos , Ecocardiografía Tridimensional/métodos , Síndrome de Guillain-Barré/complicaciones , Hallazgos Incidentales , Cefepima/uso terapéutico , Ampicilina/uso terapéutico
2.
Brasília; s.n; 17 jul. 2020.
No convencional en Portugués | BRISA, LILACS, PIE | ID: biblio-1117678

RESUMEN

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 14 artigos e 13 protocolos.


Asunto(s)
Humanos , Neumonía Viral/tratamiento farmacológico , Infecciones por Coronavirus/tratamiento farmacológico , Betacoronavirus/efectos de los fármacos , Ribavirina/uso terapéutico , Evaluación de la Tecnología Biomédica , Dexametasona/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Vancomicina/uso terapéutico , Ganciclovir/uso terapéutico , Estudios de Cohortes , Corticoesteroides/uso terapéutico , Azitromicina/uso terapéutico , Ritonavir/uso terapéutico , Oseltamivir/uso terapéutico , Antagonistas de Receptores Adrenérgicos beta 1/uso terapéutico , Lopinavir/uso terapéutico , Linezolid/uso terapéutico , Darunavir/uso terapéutico , Cobicistat/uso terapéutico , Interferón beta-1a/uso terapéutico , Adalimumab/uso terapéutico , Abatacept/uso terapéutico , Etanercept/uso terapéutico , Cefepima/uso terapéutico , Meropenem/uso terapéutico , Hidroxicloroquina/uso terapéutico
3.
Rev. chil. infectol ; 36(1): 112-114, feb. 2019. graf
Artículo en Español | LILACS | ID: biblio-1042652

RESUMEN

Resumen Las exacerbaciones pulmonares de causa infecciosa son una de las mayores complicaciones en los pacientes con fibrosis quística (FQ). Estas se asocian a un progresivo aumento en la morbilidad y mortalidad. El tratamiento antimicrobiano se realiza dependiendo del microorganismo aislado. Con frecuencia se utilizan antimicrobianos β-lactámicos, los cuales no están exentos de reacciones adversas. A continuación, se describen dos casos de neutropenia tras el uso prolongado de cefepime en pacientes con FQ.


Pulmonary exacerbations of infectious cause are one of the major complications in patients with cystic fibrosis (CF). These are associated with a progressive increase in morbidity and mortality. The treatment depending on the isolated microorganism. The β-lactam antibiotics are generally used which are not exempt from adverse reactions. Next, two report of neutropenia cases are described after prolonged use of cefepime in CF patients.


Asunto(s)
Humanos , Masculino , Femenino , Preescolar , Fibrosis Quística/tratamiento farmacológico , Cefepima/efectos adversos , Antibacterianos/efectos adversos , Neutropenia/inducido químicamente , Factores de Tiempo , Factores de Riesgo , Fibrosis Quística/complicaciones , Recuento de Leucocitos
4.
Biomédica (Bogotá) ; 38(3): 398-406, jul.-set. 2018. tab, graf
Artículo en Español | LILACS | ID: biblio-1019512

RESUMEN

Resumen Introducción. La política farmacéutica de Colombia establece la necesidad de intensificar la investigación en farmacoepidemiología a nivel nacional, especialmente en el caso de los antibióticos. Objetivo. Aportar información farmacoepidemiológica en cuanto a la efectividad, las condiciones de uso y la seguridad de la cefepima y el meropenem genéricos en un hospital de alta complejidad en Bogotá. Materiales y métodos. Se hizo un estudio descriptivo, longitudinal y retrospectivo sobre la utilización de estos medicamentos. Los datos se recolectaron de todas las historias clínicas en las cuales se registraba el uso de cefepima y meropenem. Resultados. Se incluyeron 82 pacientes tratados con cefepima y 91 con meropenem. La mayoría de ellos había estado internada en servicios diferentes a la unidad de cuidados intensivos (59,8 % con cefepima y 52,7 % con meropenem). El 21,9 % de los tratados con cefepima y el 49 % de los tratados con meropenem, tuvieron consulta con un infectólogo, en tanto que en 47 % de los primeros y en 78 % de los segundos, se hizo cultivo o antibiograma. Las condiciones más frecuentemente tratadas con cefepima fueron las infecciones de vías respiratorias (32,5 %) y, con meropenem, las infecciones genitourinarias (34,8 %). Las tasas de éxito terapéutico fueron de 61,7 % para la cefepima y de 63,0 % para el meropenem. Conclusiones. Este estudio aporta información sobre el desempeño terapéutico de dos antibióticos genéricos de uso hospitalario. No hubo reportes de falla terapéutica durante el periodo de estudio. En los casos en que no hubo respuesta al tratamiento, las causas frecuentes fueron las alteraciones farmacocinéticas, las condiciones clínicas desfavorables y la elección inadecuada del tratamiento antimicrobiano.


Abstract Introduction: The Colombian national pharmaceutical policy establishes as a strategy the generation of greater pharmaco-epidemiological research at the national level, especially in the case of antibiotic drugs. Objective: To provide local pharmaco-epidemiological evidence regarding the effectiveness, conditions of use and safety of generic meropenem and cefepime in a tertiary hospital in Bogotá. Materials and methods: We conducted a descriptive, longitudinal and retrospective drug utilization study. The data were collected from the medical histories of all the patients who had cefepime or meropenem prescribed. Results: We included 82 patients treated with cefepime and 91 treated with meropenem in the study. Most of the patients were in services different from the intensive care unit (taking cefepime: 59.8%, and meropenem: 52.7%). Only 21.9% of the patients treated with cefepime and 49% of those treated with meropenem were seen by an infectious disease specialist. The antibiogram was performed for 47% and 60% of the patients treated with cefepime and meropenem, respectively. The most frequent indication for cefepime were respiratory infections and for meropenem, genitourinary ones. Therapeutic success rates were 61.7% for cefepime and 63.0% for meropenem. Conclusions: This study contributes evidence regarding the therapeutic performance of two generic antibiotics used in tertiary hospitals. There were no reports of therapeutic failure during the study period. In the cases of non-response, pharmacokinetic alterations, unfavorable clinical conditions, and inappropriate choice of antimicrobial treatment were identified as frequent factors.


Asunto(s)
Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Adulto Joven , Medicamentos Genéricos/uso terapéutico , Centros de Atención Terciaria/estadística & datos numéricos , Cefepima/uso terapéutico , Meropenem/uso terapéutico , Antibacterianos/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Infecciones Bacterianas/tratamiento farmacológico , Estudios Retrospectivos , Resultado del Tratamiento , Medicamentos Genéricos/efectos adversos , Grupos Diagnósticos Relacionados , Colombia , Utilización de Medicamentos , Cefepima/efectos adversos , Meropenem/efectos adversos , Antibacterianos/efectos adversos
5.
Infectio ; 22(1): 55-57, ene.-mar. 2018. tab
Artículo en Español | LILACS, COLNAL | ID: biblio-892751

RESUMEN

Se presenta un caso de un hombre con diagnóstico de osteomielitis crónica con aislamiento en cultivo de hueso de Providencia rettgeri productora de carbapenemasa de tipo Nueva Delhi. El paciente presentó control de la infección por este germen con terapia antibióticacombinada con cefepime y gentamicina. Es el primer reporte de una infección por enterobacterias con este mecanismo de resistencia en la región.


We reported a case in a man with chronic osteomyelitis of an isolate of Providencia rettgeri carrying New-Delhi metallo-beta-lactamase. The isolate was obtained from the patient's bone culture. The infection was controlled with combined antibiotic therapy (cefepime and gentamicine). This is the first report of an infection produced by Enterobacteriaceae carrier of this metallo-beta-lactamase in the region.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Osteomielitis , Antibacterianos , beta-Lactamasas , Gentamicinas , Colombia , Enterobacteriaceae , Cefepima
6.
Journal of Central South University(Medical Sciences) ; (12): 856-859, 2016.
Artículo en Chino | WPRIM | ID: wpr-814951

RESUMEN

OBJECTIVE@#To determine the drug resistance of Comamonas testosteroni (C. testosteroni) by the Kirby-Bauer (K-B) method without Clinical and Laboratory Standards Institute (CLSI) explanation or the minimum inhibitory concentration (MIC) method with the standard CLSI explanation to evaluate the sensitivity of K-B method in detection of C. testosteroni.
@*METHODS@#K-B method and MIC method was used to determine the sensitivity of C. testosteroni to Piperacillin, Cefepime, Piperacillin/tazobactam, Imipenem, Meropenem, Amikacin, Gentamicin, Tobramycin, Ceftazidime and Ciprofloxacin. The interpretation standard for Pseudomonas aeruginosa was temporary used for the K-B method. The coincident rate was compared between the two methods.
@*RESULTS@#The complete or partial coincident rate for K-B method and MIC method to detect Piperacillin and Cefepime was 97.4% or 2.6%; the complete coincidence rate to detect Piperacillin/tazobactam, Imipenem and Meropenem was 100%; the complete or partial coincident rate to detect Amikacin, Gentamicin and Tobramycin 94.7% or 5.3%; the complete or partial coincident rate to detect Ceftazidime was 97.4% or 2.6%; the complete or partial coincident rate to detect Ciprofloxacin 86.8% or 10.6%, and the full non-coincidence rate was 2.6%.
@*CONCLUSION@#The results of drug sensitive test from the two methods are highly consistent. We suggest that the microbiology labs do not report the interpretive results for C. testosteroni with K-B method but report the test results.


Asunto(s)
Antibacterianos , Cefepima , Cefalosporinas , Comamonas testosteroni , Imipenem , Meropenem , Pruebas de Sensibilidad Microbiana , Ácido Penicilánico , Piperacilina , Combinación Piperacilina y Tazobactam , Pseudomonas aeruginosa , Tienamicinas
7.
Jordan Journal of Pharmaceutical Sciences. 2010; 3 (2): 145-156
en Inglés | IMEMR | ID: emr-118068

RESUMEN

Irrational use of antibiotics has fueled a major increase in prevalence of multi drug resistant pathogens, leading some to speculate that we are nearing the end of antibiotic era. The assessment of the activity of an antibiotic is crucial to the successful outcome of antimicrobial therapy. The objective of the study is to evaluate the resistance pattern between cefixime [a third generation cephalosporin] of 5micro g and cefepime [a fourth generation cephalosporin] of 30 micro g, on a total of 138 different clinical isolates namely as; Escherichia coli [30%], Staphylococcus aureus [30%], Salmonella typhi [14%], Klebsiella pneumoniae [13%] and Pseudomonas aeruginosa [13%]. The isolates were collected over a period of one year [January 2008 to January 2009] from pathological laboratories of different hospitals in Karachi, Pakistan, which comprised of 59 urine, 30 skin pus, 29 ear pus, 15 blood and 5 stool samples. In-vitro antibiotic sensitivity was performed by disk diffusion or Bauer-Kirby method using 0.5 McFarland standard. Cefepime showed good sensitivity of about 92.6% against Escherichia coli, 85% against Staphylococcus aureus, 94% against Klebsiella pneumoniae, 77.77% against Pseudomonas aeruginosa and 65% against Salmonella typhi. Cefixime showed least sensitivity against Pseudomonas aeruginosa [16.66%] and maximum effectiveness against Salmonella typhi [90%]. Results of the study indicate that cefepime is more effective for the treatment of infections caused by the above pathogens except for Salmonella typhi. It is concluded that in the face of continuing development of resistance, considerable effort will be required to maintain the effectiveness of these drug groups


Asunto(s)
Cefixima/farmacología , Cefepima/farmacología , Antibacterianos , Pruebas de Sensibilidad Microbiana , Pruebas Antimicrobianas de Difusión por Disco , Relación Dosis-Respuesta a Droga , Infecciones Bacterianas/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA